Biomarkers Market Size on Target to Reach US$ 137.7 Billion 2027

The global Biomarkers Market size to reach around US$ 137.7 Bn by 2027 and is anticipated to grow at a CAGR of around 14.1% from 2020 to 2027.

Precedence Research, Recently Published Report on “Biomarkers Market Size, Share, Growth, Trends, Segment Forecasts, Regional Outlook 2020 - 2027”. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.

Biomarker (portmanteau of biological marker) is the attribute that is accurately measured and assessed as an indicator of regular biological processes, pathogenic procedures or pharmacological reaction to a therapeutic interference. Biomarkers can be regarded as an objective action that captures what is occurring in an organism or a cell at a specific moment. Due to these attributes, biomarkers can function as early cautioning systems for the health of an individual. Most common examples of biomarkers are elevated cholesterol levels for cardiovascular disorder and high lead level for cognitive disorders. Biomarkers play a vital role in revealing associations among human biology, environmental exposures, and illness. Researchers can use biomarkers to get a clear understanding of essential biological procedures and convert research findings into applied medical and public well-being applications. A wide variety of biomarkers are employed currently. Each biological system has its particular explicit biomarkers. Several of these biomarkers are fairly easy to measure and make up part of routine health examinations.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1182

Growth Factors:

Factors such as high incidence of cancer, increasing focus on establishment of biomarker-based diagnostic methods, and growing number of contract research organizations are driving the growth of biomarkers market. The high incidence of chronic ailments, rapidly expanding applications of biomarkers in diagnostics, high funding for research and development in biopharmaceutical companies, increasing research and development activities in developing regions, and string product pipeline are further propelling the biomarkers market expansion across the globe. According to the World Health Organization, from the year 2010 to 2022, the United States is expected to observe high volume of new cancer cases and is anticipated to rise around 24% in males to more than 1 million cancer cases per year, and by around 21% in females to more than 900,000 cancer cases per year. In 2018, there were around 18 million cancer cases globally. Lung and breast cancers stood at the top position in cancer types worldwide, individually contributing 12.3% of the total cancer cases diagnosed in the year 2018.

Moreover, the constantly rising cases of chronic ailments such as cardiovascular disorders, diabetes, COPD, and asthma are contributing to the increased demand for biomarkers-based diagnostic approaches. As per the World Health Organization, cardiovascular disorders are the topmost cause of death worldwide. The WHO data further reveals that, four out of five cardiovascular disorder related deaths are because of stroke and heart attack.

Report Highlights:

• Among the type segment, safety biomarkers dominated the overall market. Increasing use of biomarkers in the drug development as well as drug discovery domains is the major reason for high market share of safety biomarkers.
• Among the diseases, cancer accounted for the largest revenue with more than 32% share in 2019. High cancer incidence worldwide and increasing demand for early detection is the major reasons for high market share of cancer. Neurological disorders are expected to grow at the topmost CAGR during the forecast time-frame. Increasing focus on development of biomarker-based diagnostic methods for the detection of neurological conditions is the major reason for the high growth.
• Drug Discovery accounted for the largest revenue in the application segment. Use of biomarkers in the pre-clinical trials and increasing investment in research and development is the key reason for high market share of drug discovery.
• F. Hoffmann-La Roche Ltd. accounted for a significant share of the global biomarkers market.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America dominated the global market with a market share of more than39%. U.S. represented the highest share in the North American region primarily due to high awareness regarding latest healthcare technology and presence of skilled researchers. Furthermore, high cancer incidence also contributed to the high market share of the United States.

Europe was the second important market chiefly due to existence of latest healthcare infrastructure and initiatives taken by the governments. The supportive reimbursement scenario in the European region is also expected to boost the demand for biomarkers market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around 16.8% in the forecast period due to high incidence of chronic disorders. Latin America and the African and Middle Eastern region will display noticeable growth.

Key Market Players and Strategies:

The major companies functioning in the worldwide biomarkers are Bio-Rad Laboratories, Inc., Epigenomics AG, Qiagen, Abbott, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Abbott, Siemens, and Thermo Fisher Scientific, Inc. among others.

High investment in the research and development along with acquisition, mergers, and collaborations are the key strategies undertaken by companies operating in the global Biomarkers market. Latest research in biomarkers have revealed that biomarker-based blood tests can help in early detection of COVID-19 in high-risk patients which can then be used to formulate treatment path well in advance.

Market Segmentation

By Type

• Validation
• Efficacy
• Safety
  

By Disease

• Neurological Diseases
• Cancer
• Immunological Diseases
• Cardiovascular Diseases
• Others
  

By Application

• Personalized Medicines
• Drug Discovery & Development
• Diagnostics
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot

Chapter 4. Biomarkers Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Biomarkers Market

5.1. Covid-19: Biomarkers Industry Impact
5.2. Biomarkers Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Biomarkers Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Biomarkers Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Biomarkers Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Rising incidences of cancer
6.1.1.2. Increasing focus on establishment of biomarker-based diagnostic methods
6.1.2. Market Restraints
6.1.2.1. Stringent regulations
6.1.3. Market Opportunities
6.1.3.1. Rapidly expanding applications of biomarkers in diagnostics
6.1.3.2. Technological advancements

Chapter 7. Global Biomarkers Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Biomarkers Market Revenue by Market Players (2016 -2019)
7.1.1.2. Biomarkers Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Biomarkers Market, By Type

8.1. Biomarkers Market, by Type, 2016-2027
8.1.1. Validation
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Efficacy
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Safety
8.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Biomarkers Market, By Disease

9.1. Biomarkers Market, by Disease, 2016-2027
9.1.1. Neurological Diseases
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Immunological Diseases
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Cardiovascular Diseases
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Biomarkers Market, By Application

10.1. Biomarkers Market, by Application, 2016-2027
10.1.1. Personalized Medicines
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Drug Discovery & Development
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Diagnostics
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Biomarkers Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Type(2016-2027)
11.1.2. Market Revenue Forecast by Disease (2016-2027)
11.1.3. Market Revenue Forecast by Application (2016-2027)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2016-2027)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2016-2027)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2016-2027)
11.2.2. Market Revenue Forecast by Disease (2016-2027)
11.2.3. Market Revenue Forecast by Application (2016-2027)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2016-2027)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2016-2027)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2016-2027)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2016-2027)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2016-2027)
11.3.2. Market Revenue Forecast by Disease (2016-2027)
11.3.3. Market Revenue Forecast by Application (2016-2027)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2016-2027)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2016-2027)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2016-2027)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2016-2027)
11.4.2. Market Revenue Forecast by Disease (2016-2027)
11.4.3. Market Revenue Forecast by Application (2016-2027)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2016-2027)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2016-2027)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2016-2027)
11.5.2. Market Revenue Forecast by Disease (2016-2027)
11.5.3. Market Revenue Forecast by Application (2016-2027)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2016-2027)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2016-2027)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2016-2027)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2016-2027)

Chapter 12. Company Profiles

12.1. Bio-Rad Laboratories, Inc.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Disease
12.1.3. Revenue, Price, and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. Qiagen
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Disease
12.2.3. Revenue, Price, and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Epigenomics AG
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Disease
12.3.3. Revenue, Price, and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Abbott
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Disease
12.4.3. Revenue, Price, and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Disease
12.5.3. Revenue, Price, and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Agilent Technologies, Inc.
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Disease
12.6.3. Revenue, Price, and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. Johnson & Johnson Services, Inc.
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Disease
12.7.3. Revenue, Price, and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Abbott
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Disease
12.8.3. Revenue, Price, and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Siemens
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Disease
12.9.3. Revenue, Price, and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Thermo Fisher Scientific, Inc.
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Disease
12.10.3. Revenue, Price, and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1182

Contact Us:

Precedence Research
​
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn| Twitter| Facebook